Haematologica: Uncover the key role of co-priced closed ring RNAs in leukemia occurrence or hopefully develop a variety of leukemia targeted therapies.

August 15, 2020 // -- Chemotherapy remains the most common and effective treatment for approximately 1.1 million new blood cancer patients worldwide each year, but the emergence of more malignant forms of leukemia in adult populations may require researchers to develop new early diagnosis strategies and new methods to bring better clinical outcomes to patients.
, in a study published in the international journal Haematologica, scientists from the National University of Singapore and others identified a common-price closed ring RNAs (circRNAs) from key genes involved in leukemia.
Photo Source: Wikipedia ASXL1 (additional sex combs-like 1) gene is an exogenous genetic reinshaper, and researchers have found mutations in the ASXL1 gene in a variety of leukemia types, including acute myeloid leukemia (AML), chronic granulocytic leukemia (CMML) and myeloid dysplitis syndrome (MDS), in addition to the mutation in patients. Poor survival prognosis in patients is directly related; recent researchers found that ASXL1 gene bits undergo selective shearing to produce circRNAs, while previous studies of circRNAs have focused on understanding the origins of these non-coding RNAs, in which researchers revealed the key role of circRNAs in regulating the evolutionary genetic blueprint and the effects of circRNAs on hema production development and leukemia.
Compared to linear RNAs, circRNAs are highly stable, high-level and highly conservative, in addition to their presence in extracellical vesicles, exosomes and body plasma, which may make it a non-invasive biomarker, by sequencing RNA, researchers can identify the cicRNA subsume from the ASXL1 gene points; 1 plays a key role in the development of leukemia, the results show that the removal of circASXL1-1 may reduce the Ubibin effect of H2AK119 (H2AK119ub), which may be achieved through the activity of BRCA-1-related protein 1 (BAP1), a de-ubigenase, which also plays a key role in the development of leukemia.
researchers have found that circASXL1-1 can bind to BAP1 to regulate its catalytic activity; this study reveals a new mechanism for regulating H2AK119ub levels in hematogenesis cells through the interaction between circasXL1-1 and BAP1. Key genes in the hematopoietic stem cell bone marrow differentiation program (HSCs), which can be targeted to restore the normal differentiation process of stem cells in leukemia and thus induce apoptosis in immature and abnormally differentiated cells, may also help develop treatment strategies for leukemia, such as oscic genetic drugs.
Finally, the researchers said that later we will continue to deeply support the use of circaSXL1-1 in analversopathy to treat malignant and non-malignant blood diseases, the results of this paper may provide some research basis and new clues for later scientists to develop new RNA-based leukemia targeted therapies.
original source: Shweta Pradip Jadhav, Nishi Kumari, Larry Ng, et al. circASXL1-1 regulates BAP1 deubiquitinase activity in leukemia, Haematologica (2019). DOI: 10.3324/haematol.2019.225961.